Are levels of pro-gastrin-releasing peptide or neuron-specific enolase at relapse prognostic factors after relapse in patients with small-cell lung cancer?

Lung Cancer

Volumn 71, Issue 2, 2011, Pages 224-228

  Hirose, Takashi ^a   Okuda, Kentaro ^a   Yamaoka, Toshimitsu ^a   Ishida, Koko ^a   Kusumoto, Sojiro ^a   Sugiyama, Tomohide ^a   Shirai, Takao ^a   Ohnshi, Tsukasa ^a   Ohmori, Tohru ^a   Adachi, Mitsuru ^a  

^a SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Neuron specific enolase; Predictive marker; Pro gastrin releasing peptide; Prognostic factor; Relapse; Small cell lung cancer

Indexed keywords

AMRUBICIN; CARBOPLATIN; CISPLATIN; ETOPOSIDE; IRINOTECAN; LACTATE DEHYDROGENASE; NEURON SPECIFIC ENOLASE; PROGASTRIN RELEASING PEPTIDE;

ADULT; AGE; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CHEMOSENSITIVITY; CLINICAL EVALUATION; FEMALE; GENDER; HUMAN; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; SURVIVAL TIME; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PEPTIDE FRAGMENTS; PHOSPHOPYRUVATE HYDRATASE; PROGNOSIS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SMALL CELL LUNG CARCINOMA; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 78650930413     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2010.05.004     Document Type: Article

References (22)

1. Schiller J.H. Topotecan in small cell lung cancer. Semin Oncol 1997, 24:S27-S33.
2. Maalouf G.E.I., Rodier J.M., Faivre S., Raymond E. Could we expect to improve survival in small cell lung cancer?. Lung Cancer 2007, 57:S30-S34.
3. Takada M., Fukuoka M., Kawahara M., Sugiura T., Yokoyama A., Yokota S., et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol 2002, 20:3054-3060.
4. Noda K., Nishiwaki Y., Kawahara M., Negoro S., Sugiura T., Yokoyama A., et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002, 346:85-91.
5. Glisson B.S. Recurrent small cell lung cancer: update. Semin Oncol 2003, 30:72-78.
6. Onoda S., Masuda N., Seto T., Eguchi K., Takiguchi Y., Isobe H., et al. Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301. J Clin Oncol 2006, 24:5448-5453.
7. von Pawel J., Schiller J.H., Shepherd F.A., Fields S.Z., Kleisbauer J.P., Chrysson N.G., et al. Topotecan versus cyclophsophamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999, 17:658-667.
8. Eckardt J.R., von Pawel J., Pujol J.L., Papai Z., Quoix E., Ardizzoni A., et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol 2007, 25:2086-2092.
9. Kubota K., Nishiwaki Y., Kakinuma R., Hojo F., Matsumoto T., Ohmatsu H., et al. Dose-intensive weekly chemotherapy for treatment of relapsed small-cell lung cancer. J Clin Oncol 1997, 15:292-296.
10. Molina R., Filella X., Auge J.M. ProGRP: a new biomarker for small cell lung cancer. Clin Biochem 2004, 37:505-511.
11. Nitta T., Fukuoka M., Masuda N., Kusunoki Y., Matsui K., Kudoh S. Significance of serum neuron-specific enolase as a predictor of relapse of small cell lung cancer. Jpn J Clin Oncol 1995, 25:179-183.
12. Yip D., Harper P.G. Predictive and prognostic factors in small cell lung cancer: current status. Lung Cancer 2000, 28:173-185.
13. Okusaka T., Eguchi K., Kasai T., Kurata T., Yamamoto N., Ohe Y., et al. Serum levels of pro-gastrin-releasing peptide for follow-up of patients with small cell lung cancer. Clin Cancer Res 1997, 3:123-127.
14. Niho S., Nishiwaki Y., Goto K., Ohmatsu H., Matsumoto T., Hojo F., et al. Significance of serum pro-gastrin-releasing peptide as a predictor or relapse of small cell lung cancer: comparative evaluation with neuron-specific enolase and carcinoembryonic antigen. Lung Cancer 2000, 27:159-167.
15. Sunaga N., Tsuchiya S., Minato K., Watanabe S., Fueki N., Hoshino H., et al. Serum pro-gastrin-releasing peptide is a useful marker for treatment monitoring and survival in small-cell lung cancer. Oncology 1999, 57:143-148.
16. Shibayama T., Ueoka H., Nishii K., Kiura K., Tabata M., Miyatake K., et al. Complementary roles of pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in diagnosis and prognosis of small-cell lung cancer. Lung Cancer 2001, 32:61-69.
17. Bremnes R.M., Sundstrom S., Aasebo U., Kaasa S., Hatlevoll R., Aamdal S., et al. The value of prognostic factors in small cell lung cancer: results from a randomized multicenter study with minimum 5 year follow-up. Lung Cancer 2003, 39:303-313.
18. Paesmans M., Scullier J.P., Lecomte J., Thiriaux J., Libert P., Sergysels R., et al. Prognostic factors for patients with small cell lung carcinoma. Cancer 2000, 89:523-533.
19. Kim Y.H., Goto K., Yoh K., Niho S., Ohmatsu H., Kubota K., et al. Performance status and sensitivity to fist-line chemotherapy are significant prognostic factor in patients with recurrent small-cell lung cancer receiving second-line chemotherapy. Cancer 2008, 113:2518-2523.
20. Ebi N., Kubota K., Nishiwaki Y., Hojo F., Matsumoto T., Kakinuma R., et al. Second-line chemotherapy for relapsed small cell lung cancer. Jpn J Clin Oncol 1997, 27:166-169.
21. Cooper E.H., Splinter T.A.W., Brown D.A., Muers M.F., Peake M.D., Pearson S.L. Evaluation of a radioimmunoassay for neuron specific enolase in small cell lung cancer. Br J Cancer 1985, 52:333-338.
22. Aoyagi K., Miyake K., Urakami K., Kashiwakuma T., Hasegawa A., Kodama T., et al. Enzyme immunoassay of immunorecative pro-gastrin-releasing peptide (31-98) as tumor marker for small-cell lung carcinoma: development and evaluation. Clin Chem 1995, 41:537-543.